Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH
Open Access
- 8 October 2025
- journal article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (11) , 6522-6530
Abstract
Zongertinib (BI 1810631), a novel orally administered HER2-specific tyrosine kinase inhibitor, has recently received accelerated approval in the United States and China for patients with advanced, previously treated HER2 mutant NSCLC. This multifaceted analysis assessed the influence of gastric pH variation on the pharmacokinetics of conventional and spray-dried dispersion (SDD) formulations of zongertinib. The influence of gastric pH on zongertinib pharmacokinetics was evaluated in male beagles. Increased gastric pH substantially reduced absorption of zongertinib as a Natrosol suspension. At low gastric pH, the SDD formulation provided improved exposure and reduced variability compared with a conventional formulation. We then evaluated the in vitro release and bioaccessibility of conventional and SDD tablet formulations of zongertinib with the tiny-TIM gastrointestinal system. Bioaccessibility was similar between the two formulations under simulated fasted conditions; however, under simulated fasted conditions with a proton pump inhibitor, the conventional formulation showed reduced bioaccessibility versus SDD. In a randomized, open-label crossover study, fasted healthy human male participants received 30 mg zongertinib as a conventional tablet formulation, an SDD tablet formulation, and as an SDD tablet formulation after multiple doses of rabeprazole 40 mg. The primary pharmacokinetic end points were area under the plasma concentration-time curve from time 0 to the last quantifiable point (AUC0-tz) and maximum plasma concentration (Cmax) of zongertinib. Cmax and AUC0-tz were ∼39% and ∼35% higher, respectively, with the SDD versus the conventional formulation. Geometric mean Cmax and AUC0-tz were similar after treatment with zongertinib SDD with and without rabeprazole. Zongertinib SDD formulation showed good bioavailability irrespective of pH, supporting further clinical development.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 28 references indexed in Scilit:
- Severe Impact of Omeprazole Timing on pH‐Sensitive Dasatinib Absorption: Unveiling Substantial Drug–Drug InteractionThe Journal of Clinical Pharmacology, 2024
- Evaluating Utilization of Tiny-TIM to Assess the Effect of Food on the Absorptions of Oral Drugs and Its Application on Biopharmaceutical ModelingJournal of Pharmaceutical Sciences, 2024
- Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An In Vivo–In Vitro–In Silico ApproachMolecular Pharmaceutics, 2023
- Utilizing Tiny-TIM to Assess the Effect of Acid-Reducing Agents on the Absorption of Orally Administered DrugsJournal of Pharmaceutical Sciences, 2021
- Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLCCritical Reviews in Oncology/Hematology, 2020
- Characterization of the GI transit conditions in Beagle dogs with a telemetric motility capsuleEuropean Journal of Pharmaceutics and Biopharmaceutics, 2019
- Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteersCancer Chemotherapy and Pharmacology, 2017
- Evaluation of two dynamic in vitro models simulating fasted and fed state conditions in the upper gastrointestinal tract (TIM-1 and tiny-TIM) for investigating the bioaccessibility of pharmaceutical compounds from oral dosage formsInternational Journal of Pharmaceutics, 2016
- Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteersThe Journal of Clinical Pharmacology, 2015
- Dose–response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypesEuropean Journal of Clinical Pharmacology, 2011